Multimodal Functional Imaging in Tumor-induced Osteomalacia: 68Ga-DOTATATE, 18F-FDG, and 68Ga-FAPI PET/CT Findings
PDF
Cite
Share
Request
Interesting Image
E-PUB
23 March 2026

Multimodal Functional Imaging in Tumor-induced Osteomalacia: 68Ga-DOTATATE, 18F-FDG, and 68Ga-FAPI PET/CT Findings

Mol Imaging Radionucl Ther. Published online 23 March 2026.
1. University of Health Sciences Türkiye, İstanbul Training and Research Hospital, Clinic of Nuclear Medicine, İstanbul, Türkiye
2. Ege University Faculty of Medicine, Department of Internal Medicine, Division of Endocrinology and Metabolism, İzmir, Türkiye
3. University of Health Sciences Türkiye, Başakşehir Çam and Sakura City Hospital, Clinic of Nuclear Medicine, İstanbul, Türkiye
No information available.
No information available
Received Date: 02.01.2026
Accepted Date: 01.03.2026
E-Pub Date: 23.03.2026
PDF
Cite
Share
Request

Abstract

Tumor-induced osteomalacia, resulting from tumoral overproduction of fibroblast growth factor 23, is a rare paraneoplastic syndrome clinically characterized by muscle weakness, bone pain, and pathological fractures. Fewer than 1,000 cases have been reported in the literature. Laboratory findings typically include hypophosphatemia, normal or decreased levels of 1.25-dihydroxy vitamin D, and normal or elevated levels of FGF23. Functional imaging methods, particularly somatostatin receptor imaging, play an important role in the localization of the tumor. In this case of tumor-induced osteomalacia, we presented the findings from gallium-68 (68Ga)-DOTATATE, 68Ga-fibroblast, and 18F-fluorodeoxyglucose positron emission tomography imaging modalities used for tumor localization.

Keywords:
Tumor-induced osteomalacia, phosphaturic mesenchymal tumors, 68Ga-DOTATATE PET/CT, 68Ga-FAPI PET/CT, 18F-FDG PET/CT

Ethics

Informed Consent: Written informed consent was obtained from all patients before imaging.

Authorship Contributions

Concept: Z.T., U.E.S., İ.Ö., M.Y., B.E.A., Design: U.E.S., İ.Ö., M.Y., B.E.A., E.A., Data Collection or Processing: U.E.S., İ.Ö., M.Y., B.E.A., E.A., Analysis or Interpretation: U.E.S., İ.Ö., M.Y., B.E.A., E.A., Literature Search: U.E.S., İ.Ö., M.Y., B.E.A., E.A., Writing: Z.T., U.E.S., E.A.
Conflict of Interest: No conflicts of interest were declared by the authors.
Financial Disclosure: The authors declare that this study has received no financial support.

References

1
Florenzano P, Hartley IR, Jimenez M, et al. Tumor--induced osteomalacia. Calcif Tissue Int. 2021;108:128-142.
2
Hautmann AH, Hautmann MG, Kölbl O, et al. Tumor--induced osteomalacia: an up-to-date review. Curr Rheumatol Rep. 2015;17:512.
3
Bosman A, Palermo A, Vanderhulst J, et al. Tumor-induced osteomalacia: a systematic clinical review of 895 cases. Calcif Tissue Int. 2022;111:367-379.
4
Rayamajhi SJ, Yeh R, Wong T, et al. Tumor-induced osteomalacia - current imaging modalities and a systematic approach for tumor localization. Clin Imaging. 2019;56:114-123.
5
Jan de Beur SM, Minisola S, Xia WB, et al. Global guidance for the recognition, diagnosis, and management of tumor-induced osteomalacia. J Intern Med. 2023;293:309-328.
6
Meyer M, Nicod Lalonde M, Testart N, et al. Detection rate of culprit tumors causing osteomalacia using somatostatin receptor PET/CT: systematic review and meta-analysis. Diagnostics (Basel). 2019;10:2. Published 2019 Dec 18.
7
Tosunoğlu Z, Bozkurt M, Erdamar S, et al. Inflammatory 68Ga FAPI-46 uptake mimicking a sister Mary Joseph’s nodule in a case of gastric signet ring cell carcinoma. Clin Nucl Med. Published online May 14, 2025.
8
Şahin ÖF, Alçın G, Ergül N, Çermik TF, Arslan E. Physiological gallbladder accumulation on 68 Ga-FAPI-46 PET/CT. Clin Nucl Med. 2024;49:e685-e686.
9
Raeisi N, Saber Tanha A, Mosavi Z, et al. Phosphaturic mesenchymal tumor in the foot detected by 99mTc-FAPI-46 SPECT/CT and 18F-FDG PET/CT. Clin Nucl Med. Published online June 4, 2025.